Sqz Biotechnologies (SQZB) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access SQZB Annual Balance Sheets →
The balance sheet data below highlights changes in Sqz Biotechnologies's financial position over recent quarters.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2023)
(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Assets
Cash & cash equivalent10.19
Cash & Short-term Investments10.00
Prepaid Expense And Other Assets Current1.89
Total Current Assets12.09
Equipment/Property/Plant Net0.98
Long-term investments2.31
Deferred, Prepaid and Other Assets, Noncurrent0.00
Other Assets, Noncurrent1.00
Operating Lease Right Of Use Asset14.42
Total Assets29.79
Liabilities
Accounts Payable, Current AC1.91
Accrued Liabilities, Current AC4.35
Other Liabilities, Current2.57
Deferred Revenue, Current DE0.00
Total Current Liabilities8.83
Total Long-term Debt0.00
Restructuring Reserve, Current RE0.17
Deferred credits, Noncurrent0.00
Other liabilities, Noncurrent18.91
Operating Lease Liability Current2.40
Operating Lease Liability Noncurrent19.08
Total Liabilities27.91
Stockholders' Equity
Common Stock Value0.03
Additional Paid In Capital Common Stock334.92
Retained Earnings / Accumulated Deficit-333.07
Other Equity0.00
Common Stockholder's Equity1.88
Total Stockholder's Equity1.88
Liabilities & Stockholder's Equity29.79
4 historic quarters locked

Sign in to unlock the full Sqz Biotechnologies balance sheet history.

About Sqz Biotechnologies Co Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0000950170-23-061187

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.